Elanco Animal Health Incorporated (ELAN)
Elanco Animal Health Incorporated Is Being Investigated For Securities Law Violations And Stockholders Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Urges Investor Participation In A Securities Fraud Inquiry Into Elanco Animal Health Incorporated
LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Elanco's President & CEO on Zenrelia Approved by FDA
Jeff Sessions, Elanco Animal Health President & CEO speak with Alix Steel and Vonnie Quinn about new pet drug Zenrelia being approved by the FDA. -------- More on Bloomberg Television and Markets Like this video?
Shareholders In Elanco Animal Health Incorporated Are Invited To Help The Schall Law Firm Look Into Possible Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy
On Thursday, the FDA approved Elanco Animal Health Incorporated's ELAN Zenrelia, a once-daily oral JAK inhibitor for the control of pruritus (itching) associated with allergic dermatitis and atopic dermatitis in dogs at least 12 months of age.
FDA approves Elanco's dermatitis treatment for dogs
The U.S. Food and Drug Administration has approved Elanco Animal Health's dermatitis treatment for dogs, the health regulator's website showed on Thursday.
Elanco Animal Health Incorporated May Have Defrauded The Public And The Schall Law Firm Seeks Investor Participation In An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Looking Into Elanco Animal Health Incorporated For Possible Securities Law Violations And Shareholders With Losses Should Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors In Elanco Animal Health Incorporated Are Urged To Join The Schall Law Firm In A Securities Fraud Investigation
LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Looking Into Elanco Animal Health Incorporated For Possible Securities Related Infractions And Affected Shareholders Should Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors With Losses In Elanco Animal Health Incorporated Are Invited By The Schall Law Firm To Participate In A Securities Fraud Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Elanco Animal Health Incorporated Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Stockholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
